The claim credits GLP-1 drugs' effects on insulin sensitivity and inflammation for changes in dermatologic conditions. No study is cited.
Recap by typeshit. Post by @lesliezrf on Instagram.
The study of over 87,000 matched patients 65 and up also found 28% fewer liver decompensation events, but no drop in heart attack or stroke and more osteoporosis diagnoses.
18:05
Dr. Stirrett walks through three pointers for people on tirzepatide, framed as part of a broader GLP-1 guide. His advice, not a set protocol.
He walks through an Azoury et al study in the October 2026 Plastic and Reconstructive Surgery that uses global health network data to compare the two weight loss routes.
U of T researchers built the AI tool with the aim of speeding up how new peptide drugs are found. The university's announcement has the details.
13:47
Ketcham runs through the habits she credits for her 90 pound loss on tirzepatide. Her personal take, not medical advice, so check with a doctor.
9:07
The endocrinologist takes on whether people can get retatrutide now, setting gray market supply against the results from Lilly's actual trials.
Loading…